d VKA were frequently reported to possess far more co-morbidities.TABLE 1 The incidence rates and incidence price ratios of thrombotic and bleeding outcomesRecurrent venous thromboembolism or stroke/systemic thrombosis Incidence rate per 100 person-years (95 CI) three.83 (3.08.76) six.81 (five.53.37) 1.16 (0.86.59) 1.18 (0.67.08) 0.96 (0.78.16) Main bleeding Incidence price per one hundred person-years (95 CI) 1.63 (1.17.28) two.97 (1.21.27) 2.74 (1.68.48) three.61 (1.78.31) 0.75 (0.59.96)Population Venous thromboembolism Atrial fibrillationAnticoagulant Direct oral anticoagulants Vitamin K antagonists Direct oral anticoagulants Vitamin K antagonistsIncidence rate ratio (95 CI) 0.78 (0.48.27)Incidence rate ratio (95 CI) 0.72 (0.54.96)Conclusions: Sufferers with morbid obesity on fixed-dose DOAC didn’t appear to possess worse outcomes compared to VKA. Even so,the strength of evidence remained low offered that benefits had been mainly observational with higher threat of confounding.ABSTRACT921 of|PB1255|Statins for Venous Occasion Reduction in Sufferers with Venous Thromboembolism: A Randomized Controlled Pilot Trial Assessing Feasibility A. Delluc1; W. Ghanima2; M. Kovacs3; S. Shivakumar4; S. Kahn5; P.M. Sandset6; C. Kearon7; M. RodgerOutcomes Clinically relevant nonmajor bleeding, n ( ) Big muscle toxicity (CK10ULN), n ( ) Muscle-related adverse events, n ( )Rosuvastatin (n = 155) two (1.three)Handle (n = 157) 1 (0.6)P value1 (0.6) 11 (7.1)0 1 (0.six)1 0.Ottawa Hospital Investigation Institute, Ottawa, Canada; 2Ostfold4Hospital, Ostfold, Norway; c-Rel Inhibitor Molecular Weight 3University of Western Ontario, London, Canada; Dalhousie University, Halifax, Canada; McGill University, Montreal, Canada; 6University of Oslo, Oslo, Norway; 7McMaster University, Hamilton, Canada Background: Statins may perhaps reduce the danger for recurrent venous thromboembolism (VTE), nonetheless, no randomized trials have explored this hypothesis. Aims: To determine feasibility of recruitment of a larger trial of secondary VTE prevention with rosuvastatin. Procedures: Sufferers with a newly diagnosed symptomatic proximal deep vein thrombosis and/or pulmonary embolism, receiving standard anticoagulation, have been randomly allocated to adjuvant rosuvastatin 20 mg when day-to-day for 180 days or no rosuvastatin for six months. Final results: Among November 2016 and December 2019, 3391 individuals have been assessed for eligibility in 6 centres. Of those individuals, 1347 (39.7 ) have been eligible and approached for participation within the trial and 312 (23.1 ) have been randomized. The imply rate of randomization was eight.2.3 sufferers monthly. Through follow-up, five recurrent VTE events had been observed, three (1.9 ) in the rosuvastatin group (two pulmonary embolism, 1 deep vein thrombosis) and two (1.3 ) within the handle group (2 pulmonary embolism) (P = 0.68). 1 important arterial event occurred inside the rosuvastatin arm and none within the handle arm (0.six vs. 0 , P = 0.50). Efficacy and security CaMK III Inhibitor site clinical outcomes are summarized in Table 1. TABLE 1 Efficacy and security clinical outcomesOutcomes Thrombotic events, n ( ) Recurrent key VTE (total) Recurrent DVT Recurrent PE Recurrent non-major VTE Arterial events (total) Myocardial infarction Stroke/TIA Acute limb ischemia Death from any bring about, n ( ) Important bleed, n ( ) 3 (1.9) 1 (0.six) 2 (1.3) 1 (0.6) 1 (0.6) 0 1 (0.six) 0 0 0 two (1.3) 0 2 (1.3) 0 0 0 0 0 1 (0.six) 1 (0.six) 0.68 0.50 1 0.50 0.50 1 0.50 1 1 1 Rosuvastatin (n = 155) Control (n = 157) P valueConclusions: In conclusion, this pilot trial established feasibility of a larger scale randomized controlled trial to determine the
